8-K filed April 27, 2026, 7:59 PM ET ticker JAGX CIK 0001585608

regulatory confidence high sentiment negative materiality 0.75

Jaguar Health granted Nasdaq extension to May 15, 2026; announces 1-for-35 reverse stock split

Jaguar Health, Inc.

Nasdaq Panel grants extension until May 15, 2026 to demonstrate compliance with $1.00 minimum bid price rule.
Company must close at $1.00+ for at least 10 consecutive business days by May 15.
Reverse stock split at 1-for-35 effective April 30, 2026; trading continues on Nasdaq under JAGX.
Reverse split approved at April 20, 2026 special meeting; no fractional shares – cash in lieu.
Panel retains jurisdiction until September 1, 2026; delisting risk persists if compliance not met.

item 3.01 item 3.03 item 5.03 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-179391
form_type: 8-K
ticker: JAGX
cik: 0001585608
company_name: Jaguar Health, Inc.
filed_at: 2026-04-27T23:59:59+00:00
discovered_at: 2026-05-14T18:02:32.525737+00:00
generated_at: 2026-05-15T03:51:11.070332+00:00
sec_items: ["3.01", "3.03", "5.03", "7.01", "9.01"]
event_type: regulatory
sentiment: negative
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-179391
json_url: https://secwatch.observer/filing/0001193125-26-179391.json
markdown_url: https://secwatch.observer/filing/0001193125-26-179391.md
text_url: https://secwatch.observer/filing/0001193125-26-179391.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/0001193125-26-179391-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1585608/000119312526179391/d109088d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

29febf435701ff486c2894191b8f7bc8b79bc5f3

Jaguar Health, Inc. received a nasdaq hearing update notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv), 5810(c)(3)(A)).

April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

1ed3755fda914724c8141d8f2429c576e283cbc6

Jaguar Health, Inc.: Filed Eleventh Amendment to Third Amended and Restated Certificate of Incorporation to effect a 1-for-35 reverse stock split (effective 2026-04-30).

the Company filed the Eleventh Amendment with the Secretary of State of the State of Delaware. The Reverse Stock Split will become effective in accordance with the terms of the Eleventh Amendment at 12:01 am Eastern Time on April 30, 2026

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

Comparable filings

AGAE

AGAE receives Nasdaq delisting notice over bid price <$1.00 and late 10-K; will appeal

Allied Gaming & Entertainment Inc. May 11, 2026, 5:09 PM ET regulatory Items 3.01, 5.03, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 5.03, 7.01, 9.01 same event type: regulatory similar materiality

This filing

April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su

Comparable filing

termination before an independent Hearings Panel (the “Panel”) by May 13, 2026. On November 4, 2025, Staff notified the Company that the bid price of the Common Stock had closed at less than $1.00 per share over 30 consecutive business days, and, as a result, did not comply with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Staff Determination was issued pursuant to Nasdaq Listing Rule 5810(c)(3)(A) on the grounds that the Company has not regained compliance with the Minimum Bid Price Rule during a 180-day compliance period and is not eligible for a second 180-day complian

Filing page SEC filing

SDOT

Nasdaq notifies Sadot Group of stockholders' equity deficiency; delisting risk

Sadot Group Inc. May 6, 2026, 7:59 PM ET regulatory Items 3.01, 5.03, 9.01

same fact type: exchange_compliance_notice, governance_change same SEC item: 3.01, 5.03, 9.01 same event type: regulatory similar materiality

This filing

April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su

Comparable filing

May 5, 2026, Sadot Group Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it no longer satisfies the minimum stockhold

Filing page SEC filing

GENC

Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing

GENCOR INDUSTRIES INC June 1, 2026, 4:09 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su

Comparable filing

May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY

Filing page SEC filing

ATNM

Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26

Actinium Pharmaceuticals, Inc. May 29, 2026, 5:10 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su

Comparable filing

May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company reported stockholders’ equity of approximately

Filing page SEC filing

CDT

CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan

CDT Equity Inc. May 28, 2026, 4:30 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su

Comparable filing

May 21, 2026, CDT Equity Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”) because the Company did not file its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”) in a timely manner, as required for continued listing on The Nasdaq Capital Market. The Notice has no immediate effect on the listing or trading of the Company’s

Filing page SEC filing

GWAV

Greenwave receives second Nasdaq delinquency notice for late Q1 2026 10-Q filing

Greenwave Technology Solutions, Inc. May 27, 2026, 5:25 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su

Comparable filing

May 21, 2026, the Company received an additional delinquency notification letter (the “Notice”) from Nasdaq due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March

Filing page SEC filing

CHAR

Charlton Aria receives Nasdaq delinquency notice for untimely Q1 10-Q filing

Charlton Aria Acquisition Corp May 27, 2026, 4:41 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su

Comparable filing

May 22, 2026, Charlton Aria Acquisition Corporation (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that

Filing page SEC filing

BRLS

Borealis Foods receives Nasdaq deficiency notice for delayed Q1 2026 10-Q; supplements prior 2025 10-K notice

Borealis Foods Inc. May 27, 2026, 4:15 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 same event type: regulatory similar materiality

This filing

April 24, 2026, Jaguar Health, Inc. (the “Company”) received a decision letter from the Nasdaq Hearings Panel (“Panel”) granting the Company’s request to continue its listing on The Nasdaq Stock Market LLC (“Nasdaq”), su

Comparable filing

May 21, 2026, a notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, because the Company has not yet filed the Q12026 Form 10-Q, the Company no longer complies with Nasdaq Lis

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-179391

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.